NEW YORK, NY —
In the United States alone, more than 21 million people suffer from diabetes, and the number is growing at a rate of 10 percent annually. This rapid growth has provided significant opportunities for pharmaceutical companies who are able to develop new therapies to address type 1 and 2 diabetes. The Paragon Report examines investing opportunities in the Biotechnology Industry and provides equity research on MannKind Corporation (NASDAQ: MNKD) and Amylin Pharmaceuticals, Inc. (NASDAQ: AMLN). Access to the full company reports can be found at:
According to Frost Sullivan research titled “US Diabetes Drug Delivery – Patient Perspective,” the future of diabetes treatments is in the convenient drug delivery methods. Type-1 diabetic patients are most likely to prefer a twice-a-day oral dosing regimen, while type-2 diabetic patients are also expected to prefer a twice-a-day oral dosing regimen or a twice-a-day patch.
MannKind’s leading drug candidate, Alfrezza, is an ultra-rapid acting inhalable insulin that (if approved) will allow diabetes patients to inhale Afrezza before a meal. MannKind is trying to show the FDA that the drug does not cause dangerous side effects to a patient’s heart.
The Paragon Report provides investors with an excellent first step in their due diligence by providing daily trading ideas, and consolidating the public information available on them. For more investment research on the biotechnology industry register with us free at www.paragonreport.com and get exclusive access to our numerous stock reports and industry newsletters.
Amylin Pharmaceuticals is engaged in the discovery, development and commercialization of drug candidates for the treatment of diabetes, obesity and other diseases. Last month shares of the company rose the most in more than six months after its Byetta drug developed with Eli Lilly Co. won expanded approval for use with the world’s top-selling insulin to treat Type 2 diabetes.
The drug brought in $559 million for San Diego-based Amylin last year, almost 85 percent of the company’s revenue, according to data Bloomberg compiled. The drug accounted for $151 million in sales for Indianapolis-based Lilly last year.
The Paragon Report has not been compensated by any of the above-mentioned publicly traded companies. Paragon Report is compensated by other third party organizations for advertising services. We act as an independent research portal and are aware that all investment entails inherent risks. Please view the full disclaimer at http://www.paragonreport.com/disclaimer
© Marketwire 2011
Article source: http://www.msnbc.msn.com/id/45131190